MIT scientists have found a way to make gene editing far safer and more accurate — a breakthrough that could reshape how we ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Danielle is an Assistant Editor at The Scientist. She has a background in neuroscience and molecular psychiatry. She has previously written for BioTechniques News, The Scientist, and Drug Discovery ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific presentations. PRME's Prime Editing platform targets multi-billion-dollar markets ...

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Significant advancements in gene silencing and gene editing offer new hope for treating rare disorders. Techniques like RNA ...

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for ...